Targeting Cytokines in GVHD Therapy
Targeting Cytokines in GVHD Therapy
复制标题
DOI：
--
复制
发表时间：
2017-06
期刊：
影响因子：
--
通讯作者：
Sandeep Kumar;H. Mohammadpour;Xuefang Cao
中科院分区：
文献类型：
--
作者：
Sandeep Kumar;H. Mohammadpour;Xuefang Cao
供体来源的同种异体造血细胞的移植导致患有各种血癌和其他血液学和免疫学疾病的患者的存活率增加。然而，这种健康益处仅限于某些患者。一个主要的并发症是移植物抗宿主病（GVHD），其发生在供体来源的免疫细胞将宿主细胞/组织识别为外来物并进行随后的破坏时。细胞因子是参与GVHD发病机制的主要一类效应分子。由活化的免疫细胞（包括T细胞）释放的促炎细胞因子导致GVHD的发作。T细胞耗竭（TCD）是预防GVHD的有效方法。几种免疫抑制药物也用于治疗GVHD。然而，这些预防和治疗策略通常导致免疫受损状态，增加感染和癌症复发的风险。考虑到中药和整体免疫抑制的不利影响，更有选择性的管理，如靶向促炎细胞因子的方法已成为一个有前途的战略，以控制GVHD。本文就细胞因子的研究进展及其在GVHD治疗中的应用作一综述。
Transplantation of donor-derived allogeneic hematopoietic cells causes increased survival in patients suffering from various blood cancers and other hematologic and immunologic diseases. However, this health benefit is limited to certain patients. One major complication is graft-versus-host disease (GVHD) that occurs when donor-derived immune cells recognize host cells/tissues as foreign and perpetrate subsequent destruction. Cytokines are a major class of effector molecules that are involved in GVHD pathogenesis. Proinflammatory cytokines released by activated immune cells including T cells lead to the onset of GVHD. T cell depletion (TCD) is an effective approach for GVHD prevention. Several immune suppressive drugs are also used to treat GVHD. However, these prophylactic and treatment strategies often lead to an immune compromised state that increases the risk for infection and cancer relapse. Considering the adverse effects of TCD and overall immune suppression, more selective managements such as approaches targeting proinflammatory cytokines have emerged as a promising strategy to control GVHD. Therefore, this work is dedicated to review recent development in the studies of cytokines and their future implication in GVHD therapy.